Lung nodule detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid cancer, negative 131I whole body scan, and undetectable serum-stimulated thyroglobulin levels: two case reports by Chan-Hee Jung et al.
JOURNAL OF MEDICAL
CASE REPORTS
Jung et al. Journal of Medical Case Reports 2012, 6:374
http://www.jmedicalcasereports.com/content/6/1/374CASE REPORT Open AccessLung nodule detected by F-18
fluorodeoxyglucose positron emission
tomography-computed tomography in patients
with papillary thyroid cancer, negative 131I whole
body scan, and undetectable serum-stimulated
thyroglobulin levels: two case reports
Chan-Hee Jung1, Hyeon-Jeong Goong1, Bo-Yeon Kim1, Jung-Mi Park2, Jeong-Ja Kwak3, Chul-Hee Kim1,
Hyun-Sook Hong4, Sung-Koo Kang1 and Ji-Oh Mok1,5*Abstract
Introduction: When a pulmonary nodular lesion is detected by F-18 fluorodeoxyglucose positron emission
tomography-computed tomography in a patient with post-surgical papillary thyroid carcinoma with undetectable
serum-stimulated thyroglobulin levels and negative 131I whole body scan, diagnosis and management of the
nodule may be confusing.
Case presentation: We describe two post-surgical patients with papillary thyroid carcinoma who showed
pulmonary nodular lesions detected by F-18 fluorodeoxyglucose positron emission tomography-computed
tomography. In both cases serum-stimulated thyroglobulin levels were undetectable and nodular lesions were not
detected by 131I whole body scan. In the first case, a 64-year-old Asian woman showed one focal increased
fluorodeoxyglucose uptake lesion in the right lower lobe of one of her lungs. Based on the histologic study, the
pulmonary nodular lesion was diagnosed as a solitary pulmonary metastasis from papillary thyroid carcinoma. In the
second case, a 59-year-old Asian woman showed a new pulmonary nodule in the right lower lobe. The computed
tomography scan of her chest revealed a 9mm nodule in the anterior basal segment and another tiny nodule in
the posterior basal segment of the right lower lobe. Six months later, both nodules had increased in size and
miliary disseminated nodules were also seen in both lungs. Based on their histology, the pulmonary nodular lesions
were considered to be primary lung adenocarcinoma.
Conclusions: The present cases emphasize that physicians should be cautious and make efforts for an accurate
diagnosis of pulmonary nodules detected on F-18 fluorodeoxyglucose positron emission tomography-computed
tomography in patients with papillary thyroid carcinoma with no evidence of metastasis such as negative 131I
whole body scan and undetectable stimulated serum thyroglobulin levels.
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The detection of a pulmonary nodule in patients who
have papillary thyroid carcinoma (PTC) often presents
us with a diagnostic dilemma because the lung is one of
the most common sites of metastasis of PTC. However,
primary lung cancer [1] and benign disease entities,
including nonspecific findings, can also coexist with
PTC. Radioiodine scans and serum thyroglobulin (Tg)
measurements are the most commonly used methods for
monitoring patients with thyroid cancer [2]. F-18 fluoro-
deoxyglucose positron emission tomography (FDG-PET)
is primarily used to detect recurrence or metastatic
disease in patients who have negative findings with 131I
whole body scan (WBS) and elevated Tg levels [3].
Although the clinical value of FDG-PET for the follow
up of patients with thyroid cancer remains controversial,
its use is rapidly increasing in clinical practice due to
concerns about recurrence or metastasis of thyroid cancer.
Also, some studies have indicated that FDG-PET is effective
in patients with undetectable Tg levels [4,5].
The detection by FDG-PET of a pulmonary nodule in
patients with PTC, even those displaying undetectable
stimulated Tg and negative 131I WBS, includes a consid-
erable variety of entities, therefore the diagnosis must be
made with caution. Although solitary metastasis to the
lung from thyroid cancer is quite rare, metastasis from
PTC can manifest as a solitary pulmonary nodule.
However, clinicians should be aware of the possibility
that pulmonary nodules mimicking metastasis on FDG-
PET with computed tomography (CT) in patients who
have PTC could be primary lung cancer.
We describe two patients who presented with pulmonary
nodular lesions by FDG-PET-CT and unexpected results
on histologic confirmation with no evidence for distant
metastasis on serum-stimulated Tg and 131I WBS.
Case presentation
Case one
A 64-year-old Asian woman underwent total thyroidect-
omy and 150mCi 131I therapy due to micro-PTC. The
FDG-PET-CT images showed one focally increased FDG
uptake lesion (maximum standardized uptake value,
SUVmax = 6.5) in the right lower lobe (RLL) of one of
her lungs 1 year after the operation and iodine ablation
therapy (Figure 1A, 1B). The lesion was a 1.3cm nodule
shown in a chest CT (Figure 1C). WBS showed no
abnormal uptake and stimulated serum Tg (Tg level
0.79ng/mL, Tg antibody (Ab) 0.1U/mL) was undetectable.
Because the tumor was located in the lower center of the
horizontal fissure, it could not be approached via
bronchoscopy or percutaneous transthoracic needle biopsy
(PTNB). Thus, we performed a RLL lobectomy for defini-
tive histologic diagnosis. A histologic examination revealed
large round-to-oval pale nuclei, intranuclear inclusion,intranuclear groove and abundant cytoplasm (Figure 2A).
Immunohistochemical staining of the cancerous cells was
positive for cytokeratin (CK) 7, thyroid transcription
factor-1 (TTF-1) and Tg (Figure 2B, 2C). Unexpectedly,
these findings were consistent with a diagnosis of solitary
pulmonary metastasis from PTC.
Case two
A 59-year-old Asian woman underwent a total thyroi-
dectomy and 150mCi 131I ablation 4 years previously.
There was no evidence for distant metastasis on a follow
up 131I WBS and stimulated serum Tg level (Tg 0.32ng/
mL, Tg Ab 0.02U/mL). However, a new pulmonary
nodule was evident in the RLL on FDG-PET-CT
(Figure 3A). Chest CT scans revealed a 9mm nodule in
the anterior basal segment and another tiny nodule in
the posterior basal segment of the RLL (Figure 3B). Six
months later, these two nodules had increased in size
and miliary disseminated nodules were present in both
lungs. We performed CT-guided PTNB and transbronchial
lung biopsy (TBLB) for differential diagnosis. Needle biop-
sied lung tissue showed well-formed glandular structures
lined by tumor cells with large hyperchromatic nuclei
(Figure 4). Based on the histology data, the pulmonary
nodular lesions were considered primary lung adenocarcin-
oma. Immunohistochemical staining revealed the cancer
cells as being positive for CK7 and TTF-1, but negative for
CK20. The patient is receiving chemotherapy for primary
lung cancer.
Discussion
When a pulmonary nodular lesion is present in a patient
with post-surgical thyroid cancer with undetectable
stimulated Tg levels, diagnosis and management of the
nodule can be confusing.
The typical radiographic appearance of pulmonary
metastases from PTC is a random distribution of
multiple nodules [6]. When a solitary nodule is present in
patients with post-surgical PTC with negative 131I WBS
and undetectable stimulated serum Tg levels, diagnosis of
the nodule is likely to be primary lung cancer, not metas-
tasis to the lung from PTC.
The first presented case represents a rare example of
metastasis of PTC presenting as a solitary pulmonary
nodule without a clinically suspicious metastasis. The
patient initially posed a diagnostic problem because the
lung mass was located in a site that was not easily
accessible to biopsy. Therefore, we performed surgical
resection for accurate diagnosis and treatment under an
initial clinical impression of primary lung cancer.
Solitary metastasis to the lung from thyroid cancer is
quite rare and 14 cases of a solitary pulmonary metasta-
sis from thyroid cancer, including our case, have been
reported [7,8]. Moreover, metastasis from micro-PTC
Figure 1 The F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (CT) scan (A: axial view, B: coronal
view) shows a focal increased FDG uptake lesion (maximum standardized uptake value, SUVmax = 6.5) (A, B). Chest CT scan shows an
enhancing nodule measuring 1.3cm in the anterobasal segment of the right lower lobe (arrow) (C).
Jung et al. Journal of Medical Case Reports 2012, 6:374 Page 3 of 6
http://www.jmedicalcasereports.com/content/6/1/374has been reported in only five cases, including our case
[7]. Seven of the 14 cases initially presented as a solitary
lung nodule without a known history of thyroid cancer,
with the remainder detected during follow-up for PTC.
In general, serum Tg measurement and radioiodine
WBS are recommended for the postoperative follow-up
of PTC [2]. However, metastatic diseases for which the
ability to take up radioactive iodine is lost are possible.
Nakada et al. reported that two of four patients with a
solitary pulmonary nodule on multidetector-CT were
proven to be metastasis from PTC but neither showed
positive radioiodine uptake. Moreover, seven of nine
patients (78%) having pulmonary metastasis showed
negative radioiodine uptake [9].
CT using iodine-rich contrast material can affect the
results of radioiodine WBS. However, we performed a chest
CT scan after T4 withdraw of radioiodine WBS in bothcases. Therefore, we think that the results of WBS were not
affected by the contrast material of the chest CT scan.
For patients with non-iodine-avid disease, the detection
of metastases may be delayed. Furthermore, it has been
reported that stimulated serum Tg determinations most
sensitively detect recurrence and metastasis. However, it
should also be noted that even an undetectable stimulated
Tg with negative Tg Ab, as in the present cases, does not
exclude a metastatic focus.
Although more recent publications have provided data
that support the use of FDG-PET scanning for indications
beyond simple disease localization in Tg-positive, radio-
active iodine scan-negative patients, the clinical application
of FDG-PET in patients with thyroid cancer with stimu-
lated Tg negative and radioactive iodine scan-negative are
not recommended routinely. However, patients with cancer
can receive medical costs benefits through the National
Figure 2 The tumor cells have large round to oval pale nuclei,
intranuclear inclusion, intranuclear groove and abundant
cytoplasm (hematoxylin and eosin × 400) (A).
Immunohistochemical stain of thyroid transcription factor-1 reveals
diffuse strong positivity in nuclei of tumor cells (B).
Immunohistochemical stain of thyroglobulin shows positive result in
cytoplasm of tumor cells (C).
Figure 3 The F-18 fluorodeoxyglucose positron emission
tomography-computed tomography (CT) scan shows a newly
appeared pulmonary nodule in the right lower lung (A). CT scan
shows a 9mm well-defined enhancing nodule in the anterobasal
segment of the right lower lung (arrow) (B).
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imaging studies are not expensive. Therefore, the use of
FDG-PET-CT is rapidly increasing in real clinical practice
in Korea. Wang et al. reported a sensitivity of 79.3% for
PET in patients with a negative iodine scan, compared withonly 18.6% sensitivity in those with positive iodine scan
[10]. In the two presented cases, the pulmonary nodule in
each patient was detected by chance. If we had not
performed FDG-PET, detection of these nodules may have
been delayed until other clinical clues developed.
The cause of a single metastasis in PTC is unknown.
Although the mechanism is unclear, macronodular single
metastatic foci and loss of capability in the uptake of
radioiodine (functional loss of iodine uptake) is respon-
sible for an evident worsening in prognosis.
However, as highlighted by the second case, pulmon-
ary nodules in patients who have PTC can be primary
lung cancer. Although the results of 131I WBS and
serum Tg were negative, several nodules of lung were
thought initially to represent a metastatic PTC due to a
typical finding for metastasis of PTC. However, pul-
monary nodular lesions were identified as pulmonary
adenocarcinoma through PTNB and TBLB. In general,
because primary lung cancer carries a poorer prognosis
than PTC, if physicians consider multiple lung nodules
Figure 4 Needle biopsied lung tissue shows well-formed glandular structures lined by tumor cells with large hyperchromatic nuclei
(hematoxylin and eosin × 200).
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worsen prognosis.
The accurate diagnosis of a pulmonary nodule in
patients with PTC is important in the choice of the opti-
mal treatment. Radioactive iodine has been the mainstay
of treatment for patients with distant metastases; young
patients having iodine-avid pulmonary micrometastases
achieved remission rates of 90% at 10 years [1]. How-
ever, for patients with metastatic disease for which the
ability to take up radioactive iodine is lost, survival is
poor (5-year and 10-year survival rate of 29% and 10%,
respectively) [11]. A study by Casara et al. reported that
the oldest patients (mean age 61.9 years) showed a ten-
dency of nonfunctioning and macronodule metastasis.
For patients with pulmonary metastases that are large or
nonresponsive to radioactive iodine, surgical resection
can be considered [11].
The challenging issue in differentiated thyroid cancer
is that there are patients with metastatic disease who
can lose their radioiodine uptake and have negative
stimulated serum Tg. A pulmonary nodule detected by
FDG-PET in patients with PTC even showing negative
for both stimulated serum Tg and 131I WBS includes a
considerable variety of entities. Thus, a diagnosis must
be made with caution.
Conclusions
The present cases were considered to offer important
information that physicians should be cautious and
make efforts for an accurate diagnosis about pulmonarynodules on FDG-PET-CT in patients who have PTC
with no evidence of metastasis such as negative 131I
WBS and undetectable stimulated serum Tg levels.
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